Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers - Episode 2

Differences Between DNA and RNA Testing for NRG1

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.

EP. 1: Prevalence of NRG1 Fusions in Lung Cancer
Now Viewing
EP. 2: Differences Between DNA and RNA Testing for NRG1
EP. 3: Standard Treatments for NRG1 Fusion+ NSCLC
EP. 4: Ongoing Research Efforts Targeting NRG1 in Lung Cancer
EP. 5: Efficacy With NRG1-Directed Agents in NSCLC
EP. 6: Prognosis, Rarity of NRG1+ Pancreatic Cancer
EP. 7: Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer
EP. 8: Standard Treatment Regimens for NRG1+ Pancreatic Cancer
EP. 9: Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer
EP. 10: Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer
EP. 11: DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer
EP. 12: A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer
EP. 13: The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
EP. 14: Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer
EP. 15: Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer
EP. 16: The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors
EP. 17: The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer
EP. 18: Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer
EP. 19: Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors
EP. 20: NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers